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Introduction: Interleukin 6 (IL-6) is a pleiotropic soluble mediator which is involved with many different
parts of inflammatory processes. Studies have shown that there is a significantly higher concentration of IL-6
in inflamed pulp tissues when compared to healthy pulp tissues. However, there are no comprehensive studies
on how IL-6 can interact with dental pulp stem cells (DPSCs) from healthy (H-DPSCs) and inflamed pulp
tissues (I-DPSCs) and how it can affect the differentiation potential of DPSCs. Therefore, I hypothesized that
IL-6 can promote osteogenesis while inhibiting neurogenesis from DPSCs. The aims of this study were to
investigate the baseline differences between the H-DPSCs and I-DPSCs, and determine how IL-6 can affect
the osteogenic and neurogenic differentiation potentials of DPSCs.
Materials and Methods: H-DPSCs and I-DPSCs were isolated and cultured from 28 teeth consisting healthy
impacted third molars (n=14) from patients with 17-27 years of age, and severely decayed molars (n=14) with
spontaneous, sharp pain from patients with 24 – 56 years of age, respectively. The levels of IL-6 from H-
DPSCs and I-DPSCs were measured by ELISA, and IL-6 and neutralizing IL-6 were added to H-DPSCs and
I-DPSCs, respectively. Immunofluorescence and Alizarin Red staining, and western blot were performed to
assess the differentiation potentials of DPSCs. The independent unpaired two-tailed Student’s t-test were
performed following quantification analysis.
Results: H-DPSCs and I-DPSCs showed similar expression of stem cell markers including CD44, CD73,
CD90, and CD105, while H-DPSCs showed lower level of IL-6 (p
Conclusion: This study showed IL-6 has the capacities to enhance osteogenesis while hindering neurogenesis
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ABSTRACT 
 
The Role of IL-6 in Osteogenic and Neurogenic Differentiation 
Potentials of Dental Pulp Stem Cells 
 
Introduction: Interleukin 6 (IL-6) is a pleiotropic soluble mediator which is involved with 
many different parts of inflammatory processes. Studies have shown that there is a 
significantly higher concentration of IL-6 in inflamed pulp tissues when compared to 
healthy pulp tissues. However, there are no comprehensive studies on how IL-6 can 
interact with dental pulp stem cells (DPSCs) from healthy (H-DPSCs) and inflamed pulp 
tissues (I-DPSCs) and how it can affect the differentiation potential of DPSCs. Therefore, I 
hypothesized that IL-6 can promote osteogenesis while inhibiting neurogenesis from 
DPSCs. The aims of this study were to investigate the baseline differences between the H-
DPSCs and I-DPSCs, and determine how IL-6 can affect the osteogenic and neurogenic 
differentiation potentials of DPSCs. 
Materials and Methods: H-DPSCs and I-DPSCs were isolated and cultured from 28 teeth 
consisting healthy impacted third molars (n=14) from patients with 17-27 years of age, and 
severely decayed molars (n=14) with spontaneous, sharp pain from patients with 24 – 56 
years of age, respectively. The levels of IL-6 from H-DPSCs and I-DPSCs were measured 
by ELISA, and IL-6 and neutralizing IL-6 were added to H-DPSCs and I-DPSCs, 
respectively. Immunofluorescence and Alizarin Red staining, and western blot were 
performed to assess the differentiation potentials of DPSCs. The independent unpaired 
two-tailed Student’s t-test were performed following quantification analysis. 
Results: H-DPSCs and I-DPSCs showed similar expression of stem cell markers including 
CD44, CD73, CD90, and CD105, while H-DPSCs showed lower level of IL-6 (p<0.001), 
lower osteogenic and higher neurogenic (p<0.001) differentiation potentials compared to I-
DPSCs. Addition of IL-6 to H-DPSCs increased the osteogenic potentials and decreased 
the neurogenic potentials (p<0.001), while neutralization of IL-6 for I-DPSCs led to 
decreased osteogenic potentials and increased neurogenic potentials (p<0.001). 
Conclusion: This study showed IL-6 has the capacities to enhance osteogenesis while 
hindering neurogenesis of DPSCs.  
 
 3 
 
TABLE OF CONTENTS 
 
ACKNOWLEDGEMENTS……………………………………………………………   1 
ABSTRACT……………………………………………………………………………   2 
LITERATURE REVIEW 
 Stem Cells in Oral Cavity……………………………………………………   4 
  Dental Pulp Stem Cells……………………………………………..   6 
 Pulp Immunology……………………………………………………………..  10 
  Role of Stem Cells in Pulpitis……………………………………….   18 
 Overview of IL-6 in Immunology…………………………………………….  21 
Role of IL-6 in Pulpitis……………………………………………….  26 
 IL-6 and Differentiation  
 IL-6 and Osteogenesis……………………………………………………….  27 
 IL-6 and Neurogenesis………………………………………………………  28 
MANUSCRIPT 
 Introduction…………………………………………………………………..   30
 Materials & Methods.……………………………………………………….    32
 Results………………………………………………………………………..     38 
 Discussion…………………………………………………………………….   58 
 Conclusions…………………………………………………………………...  65 
 References…………………………………………………………………….    67 
 4 
LITERATURE REVIEW 
 
 
Stem cells in Oral Cavity 
 
Stem cells are one of the hottest topics in the field of research including both 
medicine and dentistry in recent years, because they have been identified as a 
promising source for many clinical applications including cell therapy and tissue 
engineering.  
 
Stem cells, by their definition, are unique for two distinct characteristics which are 
the abilities to self-renew and to differentiate into different cell types (Egusa et al., 
2012). There are three types of stem cells: adult stem cells, embryonic stem cells 
and induced pluripotent stem cells. Adult stem cells and embryonic stem cells are 
naturally found in human body while induced pluripotent stem cells are 
synthetically made through genetic manipulation of somatic cells (Takahasi, 2006). 
 
Adult stem cells, including dental stem cells, are considered multipotent, meaning 
they are able to differentiate into a few different types of cells, while embryonic 
stem cells and induced pluripotent stem cells are considered pluripotent, meaning 
they can differentiate into all cell types from three germinal layers (Egusa et al., 
2012). 
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Adult stem cells are found in many tissues and organs in our body. Through self-
renewal and differentiation, adult stem cells work to keep healthy tissues and fix 
injured tissues throughout the body. Many adult stem cells are located in certain 
mesenchymal tissues and they are collectively called mesenchymal stem cells 
(MSCs) (Hortwitz et al., 2005). Originally, MSCs have been identified in the bone 
marrow, but similar types of MSCs have also been identified from many different 
areas of the body, including adipose tissue, skin and dental tissues (Egusa et al., 
2007).  
 
Recent studies have identified our oral cavity as a rich niche for many different 
types of stem cells. These cells include bone marrow-derived MSCs (BMSCs) from 
orofacial bone, dental pulp stem cells, stem cells from human exfoliated deciduous 
teeth, periodontal ligament stem cells, dental follicle stem cells, tooth germ 
progenitor cells, stem cells from the apical papilla, oral epithelial progenitor/stem 
cells, gingiva-derived MSCs, periosteum-derived stem cells and salivary gland-
derived stem cells (Egusa et al., 2012). 
 
Bone marrow stem cells possess a high replicative capacity and have the ability to 
differentiate into different connective tissue cell types. In addition, they form bone-
like structure in vivo, which makes them an attractive target for bone regeneration 
therapy (Egusa et al., 2012). The orofacial MSCs are functionally different from 
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other types of BMSCs with higher proliferation and osteogenic differentiation 
capacity based on several studies (Igarashi et al., 2007).  
 
In 2000, adult dental stem cells were first isolated from the dental pulp, then MSC-
like cells were subsequently isolated from the pulp of human deciduous teeth 
(Gronthos et al., 2000). These cells possess characteristics of stem cell, including 
the ability to self-renew and differentiate into multiple cell types (Shi et al., 2001). 
A few years after the first discovery of adult stem cells from the dental pulp, MSC-
like cells were identified again from the periodontal ligament (Seo et al., 2004). 
They have also demonstrated certain stem cell properties; additionally, they have 
shown the ability to regenerate periodontal tissues in animal models (Seo et al., 
2004). 
 
Based on active on-going research on stem cells, many promising studies are 
being conducted for stem-cell-based therapy in dentistry, focusing on tissue 
engineering and chair-side cellular grafting approaches. These studies are heading 
to more predictable regenerative outcomes in the future using stem cells in oral 
cavity (Egusa et al., 2012). These studies include alveolar bone augmentation, 
tooth regeneration, salivary gland regeneration, mandible condyle regeneration, 
tongue regeneration, cell-based immunotherapy and more (Egusa et al., 2012).  
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Dental Pulp Stem Cells 
 
As briefly mentioned above, dental pulp stem cells (DPSCs) were first isolated by 
Gronthos et al., in 2000. These cells were isolated from adult human dental pulp 
and were clonogenic and proliferative just like human BMSCs (Gronthos et al., 
2000). Although DPSCs and BMSCs showed similarities in immunophenotype in 
vitro, they behave differently when transplanted into immunocompromised mice 
(Egusa et al., 2012). DPSCs generated a dentin-like structure lined with human 
odontoblast-like cells that surrounded a pulp-like interstitial tissue when 
transplanted into immunocompromised mice, while BMSCs formed lamellar bone 
with osteocytes and surface-lining osteoblasts, surrounding a fibrous vascular 
tissue with active hematopoiesis adipocytes (Gronthos et al., 2000). This showed 
that DPSCs have the ability to form a dentin/pulp-like complex.  
 
DPSCs are commonly found within the “cell rich zone” of dental pulp tissues in 
adult teeth (D’aquino et al., 2018). DPSCs have the potential to differentiate into 
many different cell types in vitro such as osteoblasts, chondrocytes, adipocytes, 
myocytes, neurons, and hepatocytes (Karamzadeh & Eslaminjad, 2013). The 
current literatures indicate that DPSCs have the potential to differentiate into 
odontoblast, dentin, dental pulp, bone, cartilage, muscle, hair follicle, neuronal cells, 
cornea, melanocytes and endothelial cells (Kawashima, 2012). Studies have 
shown that DPSCs are often inactive, but react quickly when there’s an injury. After 
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an injury, these DPSCs react immediately to repair the tissue by differentiating into 
osteoblasts, odontoblasts and chondrocytes to produce bone, dentin and cartilage 
tissues (Potdar & Jethmalani, 2015). 
 
The identification of DPSCs depends on the presence or absence of specific cell 
surface markers. Unfortunately, there is no specific markers for DPSCs, because 
they are a heterogeneous population (Kawashima, 2012). Common surface 
markers for mesenchymal stem cells include STRO-1, CD29, CD44, CD73, CD90, 
CD105, CD146, CD166 and CD271 (Kawashima, 2012). In addition, the negative 
markers include HLA-DR and hematopoeitc antigens like CD34 and CD45 
(Karamzadeh & Eslaminjad, 2013). DPSCs also contain stemness factors such as 
OCT-3/4 and NANOG (Kawashima, 2012) 
 
These cells have shown many characteristics that make them an attractive target 
for research and future clinical applications. It has been reported that DPSCs can 
be cryopreserved and stored for long periods of time, and they can still keep their 
stem cell functions (D’aquino et al., 2018). Additionally, DPSCs have been heavily 
studied for tissue engineering to promote 3-D tissue formation (D’aquino et al., 
2018). 
From extracted human teeth, dental pulp tissues can be easily isolated and cells 
can be enzymatically released from these tissues (Karamzadeh & Eslaminjad, 
2013). After plating on a culture dish, DPSCs have the capacity to attach to the 
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dish and form a single-colony cluster usually about two weeks after culture, and 
these colonies include fibroblast-like cells and they are subjected to secondary ex 
vivo culture to expand cell numbers (Liu et al., 2006). 
 
The standard protocol for isolating DPSC from dental pulp tissue is very well 
established from Liu et al., 2006. Steps include the following: 1. Collect freshly 
extracted human teeth and place them into a sterile container with saline. Human 
third molars are the most ideal source due to the fact that it’s one of the most 
commonly extracted teeth and its optimal amount for dental pulp tissue. 2. Scrape 
the tooth surface to remove any gingival or periodontal tissues. Disinfect the tooth 
surface with iodine and 70% ethanol, and rinse 5 times with 1x phosphate-buffered 
saline (PBS). 3. Cut around the cementum-enamel junction of the tooth with 
sterilized high-speed dental burr to separate the crown and root, then the pulp 
tissue will be exposed. 4. By using sterilized tweezers, pick up the pulp tissue. 
Mince the pulp tissues with a scalpel with moisture from culture medium like alpha-
MEM. By using a mixture of collagenase type I (3mg/ml) and dispase (4mg/ml), 
incubate the tissues at 37C for about 45 minutes. 5. Add 5 volumes of culture 
medium, alpha-MEM, with 10% serum. Centrifuge the sample at 1200 rpm for 
10minutes, then suspend the cell pellet in culture medium. By using a 70-um pore 
size strainer, pass the cells to obtain single-cell suspensions. 6. Plate the cells into 
culture dishes with culture medium containing alpha-MEM with 10% fetal calf 
serum (FCS), 100 uM L-ascorbic acid 2-phosphate, 2 mM L-glutamine, penicillin 
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(100 U/ml), and streptomycin (100 mg/ml). Incubate the cells at 37C with 5% CO2. 
7. Cells grow slowly in the beginning and it takes about 2 weeks to observe single 
colonies (Liu et al., 2006).  
 
Pulp Immunology 
 
The dental pulp is a very special tissue in our body because it’s enclosed in a hard 
tissue just like our brain, and as long as this hard barrier is undamaged, the pulp 
will remain healthy and functional. However, when this barrier is damaged by 
carious lesions, dental trauma or operative dental procedures, microbial 
components can be introduced to the pulp (Bergenholtz, 1990). 
 
Pulpal inflammation involves complicated processes and various types of immune 
cells. Before looking into the details of each process of pulpal inflammatory 
responses, we will go over the basic immune components of the human pulp. 
The classic immunohistochemical analysis of the human dental pulp done by 
Pulver et al., in 1977 showed the difference between the immune components of 
normal and inflamed human pulp by looking at immunoglobulin-containing cells 
(ICC). According to their study, there was virtually no immune components that are 
necessary for immunoglobulin synthesis in the dental pulp. However, in the 
inflamed dental pulp tissues, various ICCs were detected including IgG, IgA and 
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IgE with IgG being the most prominent (Pulver et al., 1977). More recently in 2015, 
Gaudin et al., collected healthy human third molars from 42 young patients and 
quantified the immunocompetent cells in the human dental pulp by utilizing 
fluorescence-activated cell sorting, followed by flow cytometry and immunostaining 
analyses. According to their studies, leukocytes or CD45+ cells represented about 
0.94%+/-0.65% from the whole dental pulp tissues following enzymatic digestion. 
Granulocytes/neutrophils CD16+CD14+ (50.01%) cells were found to be the most 
prominent subpopulation within the CD45+ cells. CD3+ T lymphocytes (32.58%), 
CD14+ monocytes (8.93%), HLA-DR Lin1- dendritic cells (4.51%), CD3-CD56+ 
natural killer cells (2.63%), CD19+ B lymphocytes (1.65%) were also detected in 
the healthy human pulp (Gaudin et al., 2015). 
 
The detailed mechanism of pulpal inflammation involves an extensive number of 
immune cells both from innate and adaptive immune responses. Host immune 
response to microbial insult to the dentin/pulp complex is a double-edged sword, 
because if the issue is not resolved, it leads to collateral damage to the tissue, 
leading to necrosis (Cooper et al., 2014).  
When there’s a microbial invasion to the pulp, innate immune response is activated. 
When the innate immune response is not adequate to stop the insult, adaptive 
immune response is elicited to augment protective mechanisms by cellular and 
specific antibody responses (Hahn & Liewehr, 2007).  
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Generally, innate immune response does not require specific antigen recognition; 
rather, it uses molecular patterns that are commonly found in microbes (Abbas & 
Lichtman, 2003). Cells that express the major histocompatibility complex (MHC) 
will first recognize the microbes and react accordingly (Holland & Botero, 2014). 
There are type I and II MHC cells. Type I MHC cells are essentially all the 
nucleated cells in the body and they are considered “antigen-recognition” cells, and 
the type II MHC cells are considered antigen-presenting cells, because they take 
part of antigen and travel through the lymphatic system to present the antigen to T 
cells (Holland & Botoero, 2014). Usually, after recognition, these microbes are 
internalized and killed through the process called phagocytosis by immune cells 
like neutrophils and macrophages (Hahn & Liewehr, 2007). 
 
In oral mucosa, typical components of innate immunity include epithelial barriers, 
circulating cells and proteins, and these components recognize microbes or the 
substances made from microbes to stop the microbial invasion (Hahn & Liewehr, 
2007). However, the components of the innate immunity in the dentin/pulp complex 
are a bit different from those of the oral cavity. According to Hahn and Liewehr 
2007, these components include dentinal fluid and intratubular immunoglobulins, 
odontoblasts, neuropeptides and neurogenic inflammation, innate immune cells 
including natural killer (NK) cells, T cells, and immature dendritic cells (DCs) and 
their cytokines and chemokines. According to the literatures, the transition from the 
innate to adaptive immune response occurs during the progressing stages of 
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reversible pulpitis (Hahn & Liewehr, 2007). 
 
We will briefly review each component of innate immunity in the dentin/pulp 
complex. The first unique component of the innate immunity in the human pulp is 
the dentinal fluid and intratubular immunoglobulins (Hahn & Liewehr, 2007). When 
there’s positive intrapulpal pressure due to initial immune response to carious 
lesions, the outward flow of dentinal fluid is increased which can decrease the 
amount of noxious stimuli coming through the dentinal tubules (Matthews & 
Vongsavan 1994). Additionally, dentinal fluid contains serum proteins and 
immunoglobulins (Knutsson et al., 1994). Especially, when there’s deep carious 
lesion, the concentration of certain immunoglobulins including IgG1, IgA1, IgA2, 
and IgM increase in dentinal tubules (Hahn & Best, 2006). 
Another unique component of innate immunity in the dentin/pulp complex is 
odontoblasts. These cells have cellular processes that extend into the dentinal 
tubules and they are usually the first cells to encounter the microbial invasion from 
carious lesions (Hahn & Liewehr, 2097). Odontoblasts express Toll Like Receptors 
(TLRs) which are known to be part of innate immunity (Copper et al., 2014). 
Odontoblasts also secrete chemokines like CCL2 and CXCL10 which can attract 
immature Dendritic cells and leukocytes (Hahn & Liewehr, 2007). 
Neuropeptides and neurogenic inflammation also has an important role in innate 
immune response (Hahn & Liewehr, 2007). In human pulp, sensory neuropeptides 
like calcitonin gene-related peptide (CGRP), neurokinin A (NKA) and substance P 
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(SP) are often found (Awawdeh et al., 2002). When there is pulpal injury, the 
concentration of these neuropeptides increase which lead to neurogenic 
inflammation (Bowles et al., 2003). This leads to the outward flow of dentinal fluid 
and increase in interstitial tissue pressure (Hahn & Liewehr, 2007). Additionally, 
when the pulp is inflamed, the concentrations of SP and CGRP are increased 
which can lead to recruitment of immune cells including T cells and immature DCs 
(Awawdeh et al., 2002). 
 
The most common innate immune cells in the pulp include neutrophils, 
mononuclear phagocytes, NK cells, T cells and immature DCs (Hahn & Liewehr, 
2007). Neutrophils and macrophages act as phagocytes. NK cells also have an 
important role because they can promote DC maturation and produce IFN-gamma 
which activates macrophages and promotes type-I T cells responses in adaptive 
immune response (Raulet, 2004). The common cytokines secreted in the innate 
immune response include TNF-alpha, IL-1, IL-12, IL-18, IFN-gamma, IL-6 and IL-
10 (Abbas & Lichtman, 2003). The main role of TNF-alpha and IL-1 include 
promotion of extravasation of phagocytes during inflammation (Hahn & Liewehr, 
2007). IL-12, IL-18 and IFN-g are mainly associated with transitioning to the 
subsequent type 1 adaptive cellular immune response from the innate immune 
response (Trinchieri 1995). IL-10 acts as an inhibitor of macrophages and DCs to 
control innate immune responses and cell-mediated immunity (Hahn & Liewehr, 
2007).  
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Lastly, chemokines, that are produced during the innate immunity, have the ability 
to recruit neutrophils, monocytes, immature DCs, and lymphocytes to the site of 
infections (Hahn & Liewehr, 2007). 
 
Adaptive immune response is different from innate immunity in a sense that it is 
antigen specific, but its main purpose is to augment the innate immune response.  
The main players of adaptive immune response are antigen-specific lymphocytes 
and their products, such as cytokines, chemokines and antibodies (Hahn & 
Liewehr, 2007).   
 
Chemokines play an important role; for example, during pulpal inflammation, 
certain chemokine ligands are upregulated, such as monocyte chemotactic protein-
1 (CCL2/MCP-1), macrophage inflammatory protein 3-alpha (CCL20/MIP-3alpha), 
and IL-8, and these can recruit more immune cells like monocytes, memory T cells, 
NK cells, and immature DCs to amplify the immune response (Nakanishi et al., 
2001). 
Antigen presenting cells (APCs) are the main component of adaptive immunity, 
because they capture, process, and present the antigens to T cells (Holland & 
Botero, 2014). The common APCs in the inflamed pulp are DCs and macrophages 
in early pulpitis and B cells in irreversible pulpitis (Hahn & Liewehr, 2007).    
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Besides lymphocytes, macrophages are crucial in pulpitis. The main roles of 
macrophages include phagocytosis, antigen presentation and immunomodulation 
(Fujiwara & Kobayashi, 2005). Macrophages are often activated by IFN-gamma 
and once activated, they produce many different types of mediators involved with 
inflammation including IL-1, IL-2, IL-10, TNF-alpha, chemokines, prostaglandins 
and leukotrienes (Hahn & Liewehr, 2007).  
 
T cells play an important role in adaptive immune response. Once T cells are 
activated by APCs, they differentiate into different types of effectors cells including 
CD4+ T helper cells, cytotoxic CD8+ T cells, Regulatory T cells (Treg) or memory 
cells (Hahn & Liewehr, 2007). CD4+ T helper cells can be classified into type I T 
helper cells (Th1) and type II T helper cells (Th2). Th1 cells and some non T helper 
cells including CD8, NK cells or Treg produce type -1 cytokines like IFN-gamma, 
IL-2, IL-12 and TNF-alpha (Hahn & Liewehr, 2007). All of these lead to stronger 
cellular immune responses and prevent the production of type-2 cytokines. Th2 
cells and some non T helper cells can produce IL-4 and IL-10 to suppress 
macrophage activation and activate B cell proliferation and differentiation (Lebre et 
al., 2005). According to the current literatures, concentration of both type-1 and -2 
cytokines is elevated during pulpal inflammation (Hahn & Liewehr, 2007).  
 
Cytotoxic CD8+ effector T cells can also be classified into different subtypes 
including T cytotoxic-1 (Tc1), Tc2 and CD8+ Treg (Noble et al., 2006). Tc1 cells 
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produce IFN-gamma while Tc2 cells produce IL-5 (Mosmann et al.,1997). CD8 
Treg cells act to suppress immune responses by producing IL-10 (McGuirk & Mills, 
2002). However, the distribution of these cytotoxic CD8+ effector T cells in 
reversible pulpitis are not clearly known yet (Hahn & Liewehr, 2007).   
 
Even during early pulpitis, B cells appear to participate in protective mechanism, 
and their involvement increases significantly as the carious lesions progress 
toward the pulp (Hahn & Liewehr, 2007). The main functions of B cells include 
producing antibodies and cytokines like IL-4, IL-10 and IFN-gamma, and 
functioning as APCs (Bayry et al., 2005). According to immunohistochemical 
analysis from Pulver et al., 1977, IgG tends to be the most prominent antibodies in 
inflamed pulp tissues, and IgA and IgE are also commonly found during pulpal 
inflammation. Although the presence of these antibodies in inflamed pulp has been 
shown, their protective mechanisms have not been proven yet (Hahn & Liewehr, 
2007). Additionally, some suggest that even if they are protective by providing 
bacterial clearance by macrophages or continuous B-cell activation, it may still be 
too late for cases of irreversible pulpitis (Hahn & Liewehr, 2007).  
 
This may seem like an extensive review on immunology of pulpal inflammation. 
However, there are still many unanswered mechanisms even with many attempts 
being made to further the understanding of pulp immunology. The better 
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understanding of pulp immunology can lead us to clinically keep the pulp healthy 
with immunological pulp therapies in the future.    
 
Role of Stem Cells in Pulpitis 
 
Mesenchymal stem cells, especially the ones from bone marrow, are thoroughly 
examined for their surface markers that are involved in the immune response. The 
surface markers that are identified on MSCs include various cytokines like IL-1, IL-
4, IL-6, IFN-γ, TNF-α, growth factors, platelet-derived growth factor, TGF-β, 
epidermal growth factor (EGF), insulin-like growth factor (IGF), bone 
morphogenetic proteins (BMPs), chemokines, various adhesion molecules, and 
surface molecules for cell to cell interactions (Deans & Moseley, 2000 and 
Docheva, 2008). DPSCs have not been this extensively studied for their surface 
markers but many studies have shown them to have similar pattern (Leprince et al., 
2011). In addition, the current literature is indicating that there are many cytokines 
and growth factors that can influence the activity of DPSCs including the 
recruitment, proliferation and differentiation. Studies have shown that TGF- β1, 
VEGF, and FGF-2 can act as a positive regulator for chemokines for DPSC 
recruitment. Numerous factors including platelet-derived growth factor (PDGF-BB), 
VEGF, GFG-2, insulin-like growth factor (IGF-1) and TGF- β1 have been shown to 
stimulate the DPSC proliferation (Leprince et al., 2011). Additionally, TGF- β1, 
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TGF- β3, bone morphogenetic progein-7 (BMP7), BMP2, VEGF, IFN-g-2b, TNF-a, 
and IL-1 have been identified as factors that can stimulate the differentiation of 
dental stem cells (Leprince et al., 2011). All these factors are identified as positive 
regulators of dental stem cells which can eventually lead to healing of the pulp. 
 
However, there are certain factors that can reduce the healing potential of dental 
stem cells. When there is microbial insult to the pulp, inflammatory responses lead 
to interruption of DPSC differentiation and pulp homeostasis (Hozhabri et al. 2014). 
During the pulpal inflammation, there is an increase in proinflammatory cytokines 
like tumor necrosis factor alpha (TNFa) and IL-1β which can decrease the 
dentinogenic potential of DPSC and IFN-g which can prevent the proliferation of 
dental stem cells (Alongi et al. 2010). These lead to decreased collagen synthesis 
and odontogenesis, degradation of collagen, and interruption of pulp tissue 
regeneration (Hozhabri et al. 2014). With an increase in concentrations of TNFa 
and IL-1β, nuclear factor-kB (NF-kB) becomes activated, which leads to higher 
inflammatory response (Bonizzi & Karin, 2004).  A study done by Hozhabri et al. 
2014 showed that downregulation of the transcription factor NF-kB in the presence 
of TNFa and IL-1β lead to enhancement of odontoblastic differentiation and 
collagen matrix formation of DPSCs.  
 
In addition to responding to the inflammatory signals during pulpal inflammation, 
many current literatures have shown that DPSCs have anti-inflammatory and 
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immunomodulatory properties. DPSCs have been shown to inhibit activated T-cell 
response and suppress the proliferation of peripheral blood mononuclear cell 
proliferation (Leprince et al. 2011). The immunomodulatory functions of DPSCs are 
currently being thoroughly studied for their clinical application. For example, a 
recent study by Omi et al. 2016 showed that transplantation of DPSC suppressed 
inflammation in sciatic nerves for diabetic polyneuropathy in rats. Rats with 
diabetes typically show extremely reduced sciatic nerve conduction velocities and 
sciatic nerve blood flow; however, when DPSCs were transplanted into the 
unilateral hindlimb skeletal muscles for these rats, there was a significant increase 
in sciatic nerve conduction velocities and sciatic nerve blood flow (Omi et al., 2016). 
In addition, DPSC transplantation lead to significantly lower concentration of 
monocytes/macrophages and decreased tumor necrosis factor-alpha mRNA 
expression, and increased expression of IL-10 (Omi et al. 2016). In addition, 
currently, MSCs are being used for the clinical application for the treatment of graft-
versus-host-disease (GVHD) for their anti-inflammatory capacities (Leprince et al., 
2011). A study conducted by Yazid et al. showed that DPSCs isolated from 
inflamed pulp tissues showed significantly decreased immunomodulatory functions 
compared with DPSCs isolated from healthy pulp tissues. Healthy DPSCs were 
able to suppress various inflammatory mediators including TNFa, TNFB, and IL-2, 
and a significantly higher level of IL-10 was also detected in healthy DPSCs 
compared with DPSCs from inflamed tissues (Yazid et al. 2013).  The 
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immunosuppressive properties of dental stem cells can definitely influence the 
future treatment of pathogenesis of the pulp.  
 
IL-6 in Immunology 
 
Interleukin 6 (IL-6) is a pleiotropic soluble mediator that’s involved with various 
steps throughout inflammatory processes, because it induces synthesis of acute 
phase proteins like CRP, fibrinogen, serum amyloid A, and it stimulates antibody 
production and effector T cell development (Tanaka et al. 2014). IL-6 is generally 
not produced in the steady state with no inflammation (Snick, 1990). IL-6 can 
coordinate the activity of the innate and adaptive immune responses and regulate 
B and T cell responses (Garbers et al., 2018). During early inflammation, the 
release of IL-6 is promoted by proinflammatory cytokines like IL-1, TNFa, IFN-g, 
platelet-derived growth factor, and IL-3 (Barnes et al., 2011). However, in general, 
IL-6 can be secreted by many different cell types including monocytes and 
macrophages, fibroblasts, keratinocytes, astrocytes, endothelial cells, activated B 
cells and T cells (Garbers et al., 2018). IL-6 is produced during the acute phase of 
inflammation and it alters the nature of leucokyte infiltrate from neutrophils to 
monocyte/macrophages; thus controlling the transition from acute to chronic 
inflammation (Gabay, 2006). The expression of endothelial leukocyte adhesion 
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molecules including VCAM-1 and ICAM-1 increases with IL6 production which 
leads to more recruitment of leukcoytes (Barnes et al., 2011).  
 
IL-6 binds to IL-6 Receptor (IL-6R) and they bind to glycoprotein 130 (gp130) which 
initiates intracellular signaling (Schaper & Rose-John, 2015). IL-6R is expressed 
only a few cell types including hepatocytes, epithelial cells and some leukocytes 
(Scheller et al., 2011). IL-6R also exists in a soluble form as sIL-6R, and some 
cells can be stimulated by the complex of sIL-6R-IL-6, and this process has been 
called IL-6 trans-signaling (Riethmueller et al., 2017, and Rose-John & Heinrich, 
1994). 
IL-6 has three very important biological roles which include macrophage 
differentiation, bone metabolism and acute phase response (Garber et al., 2018). 
IL-6 classic signaling induces the increased expression of IL-4 receptor which 
leads to a gene expression toward M2 differentiation (Braune et al., 2017). The M2 
state of macrophage is associated with anti-inflammatory and is very important for 
regenerative functions (Garber et al., 2018). The classic signaling of IL-6 can also 
activate osteoblasts by increasing the expression of RANKL, and osteoblasts can 
secrete IL-6 which can lead to osteoclastic differentiation through trans-signaling 
(Garber et al., 2018). Lastly, IL-6 expression leads to the production of acute phase 
proteins. During inflammation, IL-6 binds to IL-6R on hepatocytes in the liver which 
leads to activation of the Janus kinase (JAK) which leads to signal transducer and 
activator of transcription (STAT) signaling and acute phase proteins including C-
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reactive protein, serum amyloid A2 protein, haptoglobin and fibrinogen (Garber et 
al., 2018).  
According to many studies, IL-6 is basically involved in almost every aspect of 
innate immune response, ranging from accumulating neutrophils at the site of 
infection to hematopoiesis (Hunter & Jones, 2017). IL-6 is known to regulate 
chemokines that activate neutrophils and is also involved with neutrophil apoptosis 
(Hunter & Jones, 2017). IL-6 also has protective roles during innate immune 
response by preventing excessive tissue damage through enhancing the transition 
from the recruitment of neutrophils to that of monocytes/macrophages (Jones, 
2005). In addition, IL-6 inhibits the activation of the transcription factor NF-kB, and 
enhances the expression of the IL-1 receptor antagonist; thus it has an important 
role in healing and resolution of inflammation (Hunter & Jones, 2017) 
 
During the acute phase of inflammation, IL-6 stimulates the production of most 
acute phase proteins (Gabay, 2006). During the initial phases of acute 
inflammation, transcription factor NF-kB gets activated and it promotes the 
transcription of the mRNA of inflammatory cytokines like tumor necrosis factor-a, 
IL-1B and IL-6 (Tanaka et al., 2014). However, IL-6 plays another important role by 
developing specific cellular and humoral immune responses like end-stage B cell 
differentiation, immunoglobulin secretion and T cell activation (Gabay, 2006). 
Additionally, IL-6 may play a role in chronic inflammation by rescuing T cells from 
apoptosis; thus enhancing a chronic inflammatory cell infiltrate (Barnes et al., 
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2011). IL-6 also has pivotal roles in adaptive immunity and one of which includes 
the induction of the maturation of B cells into plasma cells (Hunter & Jones, 2017).  
This relationship has been heavily studied in many studies and in Castleman’s 
disease, where there’s an increased concentration of IL-6 followed by B cell 
hyperplasia (Yoshizaki et al., 1989). IL-6 interacts with CD4+ T cells by inducing 
the transcriptional repressor Bcl-6 which enhances these cells to be committed to 
the follicular helper T cells which are the cells that promote B cell proliferation and 
immunoglobulin class switching (Hunter & Jones, 2017). 
 
Current literatures have shown that IL-6 has various roles in acute and chronic 
phases of inflammation, autoimmunity, endothelial cell dysfunction and 
fibrogenesis, and IL-6 has the two completely opposite roles during inflammation 
(Gabay, 2006). During acute phase of inflammation, it has anti-inflammatory 
functions by suppressing the concentration of proinflammatory cytokines like IL-1, 
while it has a detrimental effect during chronic inflammation because it promotes 
accumulation of mononuclear cells at the site of injury (Gabay, 2006). 
 
In addition, IL-6 is deeply associated with proliferation, survival and commitment of 
T cells and their cytokines (Hunter & Jones, 2017). IL-6 is involved in development 
of commitment to specific effector subsets including Th17, Th22 and Tfh subsets 
(Hunter & Jones, 2017). IL-6 binds to IL-6R on naïve T cells which leads to 
promotion of retinoic acid receptor-related orphan nuclear receptor-gamma (ROR-
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gamma) expression which is the main transcription factor for Th17 cells (Garbers 
et al., 2018). IL-6 also controls the differentiation of naïve T cells to the T follicular 
helper cells (Garbers et al., 2018).  Additionally, IL-6 can also determine the T cell 
recruitment by expressing certain chemokine receptors or IL-6 trans-signaling on 
stromal tissues that controls inflammatory chemokines. IL-6 also regulates the 
proliferation and survival of Th1 and Th2 cells (Hunter & Jones, 2017). 
IL-6 is very deeply involved with B cells because not only it promotes B cell 
differentiation and proliferation and induction of immunoglobulins by plasma, but it 
also becomes expressed by B cells (Garbers et al., 2018). IL-6 induces STAT3 
activation which induces BLIMP1 expression which is important for the terminal 
differentiation of plasma cells (Shapiro-Shelef, 2005). IL-6 also leads to expression 
of IL-7R which leads to induction of recombinase genes RAG1 and RAG2, and 
these genes are required for the B cell receptor editing (Hillion, et al., 2007). 
Additionally, IL-6 has immunomodulatory function by inducing IL-10 producing B 
regulatory cells (Rosser et al., 2014).  
Since IL-6 also has an important role as a transitioning molecule from innate to 
adaptive immune response, the impaired IL-6 activity leads to compromised 
immune response to infection (Hunter & Jones, 2015) 
IL-6 has been shown to be involved with its elevated concentration in various 
inflammatory diseases including rheumatoid arthritis, juvenile idiopathic arthritis, 
systemic lupus erythematosus, psoriasis, ankylosing spondylitis, and Crohn’s 
disease (Gabay, 2006) 
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When IL-6 was first identified, it was known for its abilities to regulate the acute-
phase immune response, activate T cells, and differentiate B cells (Hunter and 
Jones, 2015). Recently, IL-6 is being heavily studied for its hormone-like traits 
which can be associated with lipid metabolism, vascular disease, mitochondrial 
activities, insulin resistance, neuropsychological behavior and neuroendocrine 
system (Hunter and Jones, 2015).  
 
IL-6 in Pulpitis 
 
The presence of IL-6 in human dental pulp and periapical lesions was detected by 
Barkhordar et al. in 1999. According to their study, the concentration of IL-6 from 
the periapical samples from lesions and inflamed pulpal tissues was significantly 
higher than the control group by using ELISA. Many studies following Barkhordar 
et al. in 1999 showed very similar results where there is a significantly higher 
concentration of IL-6 in inflamed pulp tissues when compared with that of in 
healthy pulp tissues (Sabir & Sumidarti, 2016 and Park, 2002). As we have 
reviewed so far, IL-6 is one of the key mediators that are involved in the 
inflammatory responses. The increased concentrations of IL-6 have been detected 
in various oral diseases, and the prolonged excessive IL-6 production can lead to 
chronic inflammation, followed by tissue damage and loss of periodontal ligament 
and alveolar bone (Nibali et al., 2011).  
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Although IL-6 is being thoroughly studied currently, there is no extensive review on 
the exact function of IL-6 in the human pulp tissues. Many attempts are being 
made to investigate the role of IL-6 in pulpal inflammation in relation to stem cells.  
 
IL-6 and Osteogenesis 
 
IL-6 has been found to have both pro- and anti-inflammatory functions; therefore, 
many studies have been performed to investigate their role in inflammatory bone 
destruction following pulpal inflammation/infection. IL-6 has the ability to stimulate 
the formation of osteoclast precursors which leads to increased concentration of 
osteoclast, then to bone resorption (Kurihara et al., 1990). However, other studies 
have shown that IL-6 also has the opposite role by upregulating tissue inhibitor of 
metalloproteianses-1 and inducing acute-phase proteins that have anti-
inflammatory properties (Akira et al., 1993). A study done by Balto et al., in 2001 
conducted experiments to investigate the net effect of IL-6 in inflammatory bone 
destruction by using IL-6-/- (knockout) mice. According to the analysis on the 
samples from the periapical lesions caused by pulpal infection, bone destruction 
was significantly increased in IL-6 knockout mice, meaning IL-6 has anti-
inflammatory functions and can modulate bone destruction in vivo (Balto et al., 
2001).  
Studies have shown that the levels of IL-6 and IL-6R are increased during 
osteogenic differentiation in bone marrow mesenchymal stem cells (BM-MSCs) 
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(Xie et al., 2018). The IL-6 and IL-6R complex activate the downstream STAT3 
signaling pathway which leads to osteogenic differentiation in BM-MSCs (Chalaris 
et al., 2011). The neutralizing antibodies against IL-6 or IL-6R have shown to 
decrease the osteogenic differentiation of BM-MSCs to confirm their role (Xiet et al., 
2018). 
 
There are many other studies that indicate the role of IL-6 in promoting osteogenic 
differentiation through many different pathways. For example, a study done by 
Huang et al. in 2018 showed that IL-6 and soluble IL-6R can increase BMP-2 
induced osteogenic and adipogenic differentiation of human BMSCs through 
increasing BMPR1A-mediated BMP/Smad and p38 MAPK pathways (Huang et al., 
2018). 
 
IL-6 and Neurogenic Differentiation 
 
Neural stem cells (NSCs) are known to have a very high neurogenic differential 
potential which can replace damaged cells, and regenerate and re-myelinate host 
axons through paracrine effects (Jung et al., 2016). Similar to NSCs, DPSCs also 
have the capacity to differentiate into neural-like cells; therefore, they are a good 
candidate for neural regeneration (Ibarretxe et al., 2012). For an example, a study 
done by Jung et al. in 2016 showed that when DPSCs were transplanted into the 
 29 
brain and injured spinal cord in rats, they were able to survive and express 
neuronal markers including nestin and Sox2. Therefore, DPSCs, especially with 
their cranial neural crest lineage, are an attractive source for neural regeneration 
and repair in nerve-related diseases in addition to their immunomodulatory factors 
(Luo et al., 2018). 
 
IL-6 also plays an important role in neurogenic inflammation. IL-6 can induce the 
generation of neurogenic inflammation and pain generation (Ebbinghaus et al., 
2015). However, there is no studies conducted on its role on neurogenic 
differentiation of mesenchymal stem cells.   
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MANUSCRIPT 
 
Introduction 
Interleukin 6 (IL-6) is a pleiotropic soluble mediator that is involved in various steps 
throughout inflammatory processes (Tanaka et al. 2014). IL-6 can coordinate the 
activity of the innate and adaptive immune responses and regulate B and T cell 
responses (Garbers et al., 2018). IL-6 is produced during the acute phase of 
inflammation and it alters the nature of leukocyte infiltrate from neutrophils to 
monocyte/macrophages; thus controlling the transition from acute to chronic 
inflammation (Gabay, 2006). Although IL-6 has been thoroughly investigated for its 
role and relationships with various types of immune cells, there is not yet an 
extensive review on its relationship with dental pulp stem cells (DPSCs).  
DPSCs were first isolated from adult human dental pulp, and their clonogenic and 
proliferative properties were similar to human bone marrow mesenchymal stem 
cells (BMSCs) (Gronthos et al., 2000). DPSCs have the potential to differentiate 
into many different cell types in vitro such as osteoblasts, chondrocytes, adipocytes, 
myocytes, neurons, and hepatocytes (Karamzadeh & Eslaminjad, 2013). 
Furthermore, recent studies have shown DPSCs have immunomodulatory effect on 
immune cells (Lee et al., 2016 & Zhao et al., 2012). In addition, a subset of MSCs 
also has been isolated from inflamed human pulps (I-DPSCs) and shown the full 
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capability of proliferation and multi-potent differentiation as compared to those from 
healthy pulps (H-DPSCs) (Alongi et al., 2010 & Pereira et al., 2012). 
Studies have shown that the level of IL-6 is increased during osteogenic 
differentiation in BMSCs (Xie et al., 2018). IL-6 can activate the downstream 
STAT3 signaling pathway which leads to osteogenic differentiation of BMSCs 
(Chalaris et al., 2011). The neutralizing antibodies against IL-6 have shown to 
decrease the osteogenic differentiation of BM-MSCs to confirm their role (Xie et al., 
2018). IL-6 also plays an important role in neurogenic inflammation. IL-6 can 
induce the generation of neurogenic inflammation and pain (Ebbinghaus et al., 
2015). However, there is no extensive study conducted on its role on neurogenic 
differentiation of MSCs. 
Including the study done by Barkhordar et al., in 1999, many studies have shown 
that there is a significantly higher concentration of IL-6 in inflamed pulp tissues 
when compared with that of in healthy pulp tissues (Sabir & Sumidarti, 2016, Park, 
2002). However, there are no studies to demonstrate the interaction of IL-6 with 
DPSCs in healthy and inflamed pulp tissues and the effect of IL-6 on the 
differentiation potential of DPSCs. 
Therefore, I hypothesized that IL-6 can promote osteogenesis while inhibiting 
neurogenesis from DPSCs. The aims of this study were to investigate the baseline 
differences between the H-DPSCs and I-DPSCs, and determine how IL-6 can 
affect the osteogenic and neurogenic differentiation potentials of DPSCs. 
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Materials and Methods 
Subjects and Primary Culturing 
Healthy impacted third molars from patients with 17-27 years of age, and severely 
decayed molars with no restorability and spontaneous, sharp shooting pain from 
patients with 24-56 years of age were collected at the Oral Surgery Clinic at the 
University of Pennsylvania School of Dental Medicine after informed consent was 
obtained following the protocol approved by the Institutional Review Board of the 
University of Pennsylvania.  
A total of 20 patients with ages, that range from 17 to 56 years of age, with no 
systemic diseases were seen at the Oral Surgery Clinic at the Penn Dental 
Medicine, and a total of 28 molars were extracted from these patients. Eight 
healthy impacted third molars from four patients were used for four cultures of 
primary culturing of H-DPSCs (two teeth from each person per culture); two healthy 
impacted third molars for H & E staining; four healthy impacted third molars for 
Toluidine Blue staining. Eight severely decayed molars from four patients were 
used for four cultures of primary culturing of I-DPSCs (two teeth from each person 
per culture); two severely decayed molars for H & E staining; four severely 
decayed molars for Toluidine Blue staining.  
Tooth surfaces were scraped to remove gingival tissues and they were disinfected 
with 70% ethanol and rinsed with 1x phosphate-buffered saline (PBS). By using a 
sterilized dental bur, each tooth was cut at the cementum-enamel junction, and the 
pulp tissue was gently taken out with sterilized tweezers. Only the coronal portion 
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of pulp tissue from severely decayed teeth was used for I-DPSC culturing to 
ensure only the inflamed areas are being affected. The pulp tissues were minced 
with a scalpel and were digested in a solution of 3mg/ml collagenase type I 
(Worthington Biochem, Freehold, NJ) and 4mg/ml dispase (Boehringer Mannheim) 
for 1 hour at 37 °C. The single-cell suspensions were obtained by using a 70- µm 
pore size strainer (Falcon) to pass the cells. Cells were plated into culture dishes 
with culture medium containing a-MEM (Invitrogen) with 10% fetal bovine serum 
(FBS) (Gemini), 100 µM L-ascorbic acid 2-phopshate (Wako Pure Chemicals, 
Osaka) / 2mM L-glutamine/ 100 units/ml penicillin, 100 µg/ml streptomycin 
(Biofluids, Rockville, MD), and they were incubated at 37°C in 5% CO2.  
 
Colony-Forming Unit-Fibroblasts (CFU-F) Assay and Proliferation Assay 
After 14 days of culturing, cells were fixed with 4% formalin and then stained with 
0.1% toluidine blue for the assessment of colony-forming efficiency. A colony was 
defined as aggregates that are consisted of more than 50 cells. The proliferation 
rate of subconfluent cultures of healthy and inflamed DPSCs was investigated with 
bromodeoxyuridine (BrdU) incorporation for 10 hours by using a BrdU Staining Kit 
(Invitrogen) following the manufacturer’s instructions. By using ten image areas per 
subject, BrdU-positive and total cell numbers were counted. The BrdU-positive 
cells were quantified as a percentage of the total number of cells. 
In order to investigate the healthy and inflamed pulp tissues, the samples were 
fixed with 4% paraformaldehyde (Sigma-Aldrich), decalcified with 5% EDTA, then 
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embedded in paraffin. These paraffin sections (6µM) were then stained with 
hematoxylin and eosin (H&E). The ImageJ software was used to analyze the 
stained pulp tissues. 
 
Flow Cytometric Analysis  
In order to analyze the baseline stem cell markers for DPSCs, healthy and 
inflamed DPSCs were incubated with various antibodies, including CD44, CD73, 
CD90, CD105, CD34, and CD45. CD44, CD73, CD90, and CD105 were used as a 
positive marker while CD34 and CD45 were used as a negative marker for DPSCs. 
The FACSCalibur with CellQuest software was used for the analysis.  
 
Immunofluorescence Staining 
In order to perform immunofluorescence staining, frozen sections were prepared. 
The slides were stained with CD3, CD105 and IL-6, followed by secondary 
antibody staining.  
For the assessment of neurogenic differentiation of healthy and inflamed DPSCs, 
the samples were cultured on 4-well chamber slides (Nunc, Rochester, NY, USA) 
(2 x 103/well). They were incubated with neurogenic markers including MAP2 and 
NeuN before and after the treatment with IL-6, followed by neurogenic 
differentiation. The secondary antibody staining was done for all the slides, then 
they were mounted with Vectashield mounting medium containing DAPI. 
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Enzyme-linked Immunosorbent (ELISA) Assay 
The levels of IL-6 from the culture supernatant from healthy and inflamed DPSCs 
were measured with the Human IL-6 ELISA MAXTM Deluxe kit purchased from 
Biolegend, following the manufacturer’s instructions.  
 
IL-6 Treatment to Healthy and Inflamed DPSCs  
In order to examine the role of IL-6 in osteogenic and neurogenic potentials of 
DPSCs from the healthy and inflamed pulp tissues, IL-6 was added. Since the level 
of IL-6 in the culture supernatant from healthy DPSCs was lower than that of 
inflamed DPSCs, IL-6 molecules (R&D Systems) were added to the culture 
medium. In contrast, neutralizing IL-6 antibodies (Biolegend) (10µL per 1mL 
medium) were added to the culture medium of inflamed DPSCs to reduce the 
effects of IL-6. 
 
Osteogenic Differentiation Assay 
For the assessment on the difference between the healthy and inflamed DPSCs 
and on the role of IL-6 on DPSCs, four different sets of DPSCs were used. Healthy 
DPSCs, Inflamed DPSCs, healthy DPSCs treated with additive IL-6 and inflamed 
DPSCs with neutralizing IL-6 were loaded at 1 x 106 per well into a 6-well plate. 
Osteogenic differentiation was induced when cells reached 100% confluence. The 
osteogenic medium contained 2mM ß-glycerophosphate (Sigma), 100 µM L-
ascorbic acid 2-phosphate (Sigma) and 10 nM dexamethasone (Sigma). In order to 
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assess the osteogenic markers including OCN and Runx2, total protein was 
isolated from cultured DPSCs after 14 days of osteogenic induction, and then the 
Western blot analysis was performed. After 2 weeks of osteogenic induction, the 
cells were stained with 1% alizarin red-S (Sigma) and the ImageJ software was 
used for the analysis.  
 
Neurogenic Differentiation Assay 
Similar to the osteogenic differentiation assay, four different sets of DPSCs were 
used including healthy DPSCs, inflamed DPSCs, healthy DPSCs treated with 
additive IL-6 and inflamed DPSCs with neutralizing IL-6. These cells were then 
loaded at 1 x 106 per well into a 6-well plate. Neurogenic differentiation was 
induced when cells reached 100% confluence and the neurogenic medium 
contained DMEM (Invitrogen) with 10% FBS, 1 x N-2 supplement (Life 
Technologies), 100 U/mL penicillin, 100 µg/mL streptomycin, 10 ng/mL fibroblast 
growth factor 2, and 10 ng/mL epidermal growth factor (R&D Systems, Minneapolis, 
MN, USA). After 14 days of neurogenic induction, the neurogenic markers 
including NeuN and MAP2 were assessed through the Western blot analysis after 
total protein was isolated from the cultured DPSCs. 
 
Western Blot Analysis 
The M-PER mammalian protein extraction reagent (Thermo, Rockford, IL, USA) 
was used to extract total protein from the samples. The concentrations of proteins 
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were measured by using protein concentration assay (Bio-Rad Laboratories). 20 
µg of proteins were applied and separated by SDS PAGE gel and they were 
transferred to 0.2 µm nitrocellulose membranes (Millipore). The membranes were 
then blocked with 5% non-fat dry milk and 0.1% tween-20 for 1 hour. The 
membranes were incubated overnight with the primary antibodies diluted in 
blocking solution following manufacturer’s instructions. Antibodies to human Runx2, 
ALP, NeuN, and MAP2 were purchased from Santa Cruz Biotechnology, Inc., and 
antibodies to mouse ß-actin were purchased from Abcam. For the secondary 
binding, the membranes were incubated for 1 hour in HRP-conjugated secondary 
antibody (Santa Cruz Biotechnology, Inc.). The SuperSignal West Pico 
Chemiluminescent Substrate (Thermo Fisher Scientific) and BioMax film (Kodak) 
were used to detect the immunoreactive proteins. With the ImageJ software, the 
bands were analyzed with ß-actin as a control.  
  
Statistical Analysis 
The independent unpaired two-tailed Student’s t-tests were used when comparing 
between two groups. P-values less than 0.05 were considered statistically 
significant.   
  
Results 
Baseline characteristics of Healthy and Inflamed Pulp Tissues 
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Although there are many studies on analyzing the differences between the DPSCs 
from healthy pulp tissues (H-DPSCs) and the ones from inflamed pulp tissues (I-
DPSCs), functions of these DPSCs vary slightly from each studies. Therefore, we 
used our own samples to investigate the baseline characteristics of H-DPSCs and 
I-DPSCs first.  
As mentioned above, the results come from four different sets of H-DPSCs and I-
DPSCs for culturing, two different sets of pulp tissues for healthy and inflamed pulp 
tissues for H&E staining, and four different sets of H-DPSCs and I-DPSCs for 
Toluidine Blue staining for assessment of proliferation rate. 
  
Figure 1. H & E staining of healthy and inflamed pulp tissues 
 
   20xMag 20xMag 
  Figure 1a. Healthy pulp tissue        Figure 1b. Inflamed pulp tissue  
 
The H & E staining of healthy and inflamed pulp tissues serve two purposes. Firstly, 
it is to confirm that diagnosis on healthy and inflamed teeth are correctly made by 
examining the infiltrates of the pulp tissues. Secondly, it is used for general 
characterization of healthy and inflamed pulp tissues. As seen in figure 1, normal 
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pulp tissue is made up with blood vessels, connective tissues, red blood cells, 
small number of lymphatic cells and nervous elements, while inflamed pulp tissue 
is filled with immune cells, indicative of severe inflammation.  
Figure 2. Immunofluorescence staining of healthy and inflamed pulp tissues 
 
     
   2a.  H-DPSC with CD105 (g)              2b. I-DPSC with CD105(g)  
           
      2c. H DPSC with CD3 (g)               2d. I-DPSC with CD3 (g)  
           
     2e. H-DPSC with IL-6 (g)                    2f. I-DPSC with IL-6 (g) 
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Immunofluorescence staining was performed to assess the difference between the 
baseline characteristics of healthy and inflamed pulp tissues from frozen sections. 
CD105 is a common surface marker for DPSCs, while CD3 and IL-6 are common 
indicators of inflammation. As seen by the quantification analysis, while there was 
no statistical difference between healthy (12.4% 41± 1.8) and inflamed (15% ± 4.2) 
pulp tissues for CD 105, there were statistical differences between healthy and 
inflamed pulp tissues for CD3 and IL-6 (p=0.000028 and p=00032, respectively). 
The positively stained cells for CD3 were 4.69 % ± 2.7% and 19.3% ± 4% for 
healthy and inflamed pulp tissues respectively, and for IL-6, they were 4.41 % ± 
2.87% and 17.7% ± 5.79 % for healthy and inflamed pulp tissues respectively.  
 
Baseline characteristics of Healthy and Inflamed DPSCs 
 
Figure 3. CFU-F Assay 
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Figure 3c. Mean Number of Colonies Per 10,000 Cells Plated per well 
 
In order to assess the proliferation capacities of H-DPSCs and I-DPSCs, the mean 
number of colonies per 10,000 cells plated per well for primary culturing was 
measured. The mean number of colonies for H-DPSCs was 32 with standard 
deviation of 14.45, while it was 13.75 with standard deviation of 7.89 for I-DPSCs 
with p value of 0.068. Due to the small sample size, even though there is a 
substantial difference between the two groups, there was no statistical significance. 
Each group had 4 samples, and H-DPSCs formed more colonies when compared 
to I-DPSCs in general as seen in figure 3.  
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Figure 4. Proliferation assay 
         
Figure 4a. H-DPSC                  Figure 4b. I-DPSC 
 
 
 
           Figure 4c. BrdU positive cells (% Total) 
 
In addition to Toluidine Blue staining, the subconfluent H-DPSCs and I-DPSCs 
were stained with BrdU for the assessment of proliferation capacities. The results 
from BrdU staining was in agreement of the results from Toluidine Blue staining. H-
DPSCs had an average of 70.3 % ± 7.6 positively stained cells, while I-DPSCs had 
an average of 49.16 % ± 4.13 positively stained cells. The results indicate that 
even though DPSCs isolated from both healthy and inflamed pulp tissues have a 
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high proliferation rate, H-DPSCs had a higher proliferation capacities compared to 
I-DPSCs. 
 
Figure 5. Flow cytometric analysis 
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Marker % Gated Mean
All 100.00 87.09
M1 99.79 87.27
File: CD90-Inf3.014
Acquisition Date: 20-Sep-17
Gate: G1
Gated Events: 10308
Operator: Administrator
100 101 10 103 104
FL2-H
99.8%
I-DPSC
CD73
Marker % Gated Mean
All 100.00 91.24
M1 99.14 92.01
File: CD73-N2.004
Acquisition Date: 20-Sep-17
Gate: G1
Gated Events: 10809
Operator: Administrator
100 101 102 103 104
FL2-H
99.1%
H-DPSC
CD90
Marker % Gated Mean
All 100.00 87.12
M1 99.77 87.31
File: CD73-Inf3.011
Acquisition Date: 20-Sep-17
Gate: G1
Gated Events: 11170
Operator: Administrator
100 10 10 103 104
FL2-H
99.8%
I-DPSC
CD90
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 Table 1.  
Marker Normal DPSC 
(% Gated) 
Inflamed DPSC 
(% Gated) 
CD44 85.6 99.6 
CD73 99.5 99.8 
CD90 99.1 99.8 
CD105 99.9 99.9 
CD34 0.24 0.01 
CD45 0.26 0.07 
 
Marker % Gated Mean
All 100.00 441.25
M1 99.86 441.85
File: CD44-N2.008
Acquisition Date: 20-Sep-17
Gate: G1
Gated Events: 10296
Operator: Administrator
100 101 102 103 104
FL2-H
99.9%
H-DPSC
CD105
Marker % Gated Mean
All 100.00 276.87
M1 99.88 277.20
File: CD44-Inf3.015
Acquisition Date: 20-Sep-17
Gate: G1
Gated Events: 10878
Operator: Administrator
100 101 102 103 104
FL2-H
99.9%
I-DPSC
CD105
Marker % Gated Mean
All 100.00 1.18
M1 0.24 8.65
File: CD45-N2.005
Acquisition Date: 20-Sep-17
Gate: G1
Gated Events: 9872
Operator: Administrator
100 101 102 103 104
FL2-H
0.24%
H-DPSC
CD34
Marker % Gated Mean
All 100.00 1.04
M1 0.01 69.78
File: CD45-Inf3.012
Acquisition Date: 20-Sep-17
Gate: G1
Gated Events: 10701
Operator: Administrator
100 101 102 103 104
FL2-H
0.01%
I-DPSC
CD34
Marker % Gated Mean
All 100.00 1.18
M1 0.26 8.16
File: CD34-N2.002
Acquisition Date: 20-Sep-17
Gate: G1
Gated Events: 10026
Operator: Administrator
100 101 102 103 104
FL2-H
0.26%
H-DPSC
CD45
Marker % Gated Mean
All 100.00 1.17
M1 0.07 190.38
File: CD34-Inf3.009
Acquisition Date: 20-Sep-17
Gate: G1
Gated Events: 10712
Operator: Administrator
100 101 102 103 104
FL2-H
0.07%
I-DPSC
CD45
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The flow cytometric analysis was performed on H-DPSCs and I-DPSCs to confirm 
the purity of stem cell components in the cell culture and to assess the difference 
between the H-DPSCs and I-DPSCs. CD44, CD73, CD90 and CD105 are 
considered typical positive stem cell markers while CD34 and CD45 are 
considered negative markers. As summarized in Table 1, both H-DPSCs and I-
DPSCs were positive for CD44, CD73, CD90 and CD105, while both were negative 
for CD34 and CD45. These results indicate that the cell cultures for both H-DPSCs 
and I-DPSCs were purely composed of DPSCs, and there was no statistical 
difference between them with regards to these markers.   
 
Presence of IL-6 in Culture Supernatant from Healthy and Inflamed DPSCs 
As mentioned by Barkhordar et al. in 1999, the inflamed pulp tissues contain higher 
concentration of IL-6 compared to the healthy pulp tissues. ELISA was performed 
on the culture supernatant from healthy and inflamed DPSCs to investigate if there 
is a difference in the level of IL-6. On average from our samples, H-DPSCs 
contained 16pg/mL of IL-6 in their culture medium while I-DPSCs contained 
119.5pg/mL of IL-6. These results indicate that I-DPSCs have the capacity to 
produce a higher concentration of IL-6 with statistical significance (p value < 0.01).  
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Figure 6. Concentration of IL-6 in culture supernatant from H-DPSCs and I-DPSCs 
 
 
Comparison on Osteogenic Differentiation Potentials between Healthy and 
Inflamed DPSCs 
 
Figure 7. Osteogenic differentiation potential with Alizarin Red staining and 
western blotting 
 
          
     Figure 7a. H-DPSCs         Figure 7b. I-DPSCs 
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              Figure 7c. Western Blotting for OCN 
 
                       
                     
             Figure 7d. Western Blotting for Runx2 
 
 
Although DPSCs are known to have high osteogenic differentiation potentials, 
there are still conflicting data on the difference between H-DPSCs and I-DPSCs for 
their capacities for osteogenic differentiation. Therefore, our samples were induced 
for osteogenesis, and the Alizarin Red staining and the western blotting analysis 
were performed to assess the difference between H-DPSCs and I-DPSCs. Figure 
6 shows both samples have osteogenic differentiation potential. Interestingly, I-
DPSCs had stronger Alizarin Red staining and thicker bands for osteogenic 
markers, Osteocalcin (OCN) and Runx2. 
 
OCN 37KD 
ß-Actin 42KD 
Runx2 
ß-Actin 
65KD 
42KD 
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Comparison on Neurogenic Differentiation Potentials between Healthy and 
Inflamed DPSCs 
 
Figure 8. Neurogenic differentiation potential analysis with immunofluorescent 
staining and western blotting 
 
 
    
        Figure 8a. H-DPSC- MAP2               Figure 8b. I-DPSC – MAP2 
     
        Figure 8c. H-DPSC – NeuN                Figure 8d. I-DPSC - NeuN 
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                  Figure 8e. Western Blotting with NeuN 
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                   Figure 8f. Western Blotting with GAD6 
 
In addition to osteogenic differentiation, DPSCs are also capable of neurogenesis 
(Ibarretxe et al., 2012). Our DPSCs samples were induced for neurogenesis, and 
immunofluorescence and western blotting were performed to investigate if there is 
any difference between H-DPSCs and I-DPSCs.  
Immunofluorescences showed that H-DPSCs are more highly stained with 
neurogenic markers including MAP2 and NeuN than I-DPSCs. According to the 
quantification analysis, 97.2 % (± 2.3%) and 98.3 % (± 1.2%) of H-DPSC samples 
were positively stained for MAP2 and NeuN respectively, while 68.5% (± 13.3%) 
and 61.7% (±11%) of I-DPSCs samples were positively stained for MAP2 and 
NeuN respectively. Likewise, the expression of NeuN and GAD6 was more 
strongly detected in H-DPSCs compared with I-DPSCs. 
 
Effects of IL-6 on Osteogenic and Neurogenic Differentiation Potentials of 
DPSCs 
 
GAD6 65KD
ß-Actin 42KD
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Figure 9. Osteogenic differentiation potential of IL-6 treated H-DPSC and I-DPSC 
 
         
           Figure 9a. H-DPSCs        Figure 9b. H-DPSCs with additive IL-6 
          
           Figure 9c. I-DPSCs      Figure 9d. I-DPSCs with neutralizing IL6 
 
 
 
                    Figure 9e. Western Blotting for OCN 
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                     Figure 9f. Western Blotting for Runx2 
 
  
Since our findings indicate that there are statistical differences between H-DPSCs 
and I-DPSCs on the secretion of IL-6 during culturing, and osteogenic and 
neurogenic differentiation, additional experiments were performed to investigate 
the role of IL-6 on the differentiation potentials of two different types of DPSCs.  
Based on Alizarin Red staining and western blotting analysis, IL-6 has an effect on 
DPSCs for their osteogenic differentiation potentials. Upon stimulation with IL-6, H-
DPSCs had higher osteogenic differentiation, as seen by stronger Alizarin Red 
staining and stronger expression of osteogenic markers including OCN and Runx2 
compared to those from non-stimulated H-DPSCs.  
In contrast, when neutralizing IL-6 was added to prevent the action of IL-6 for I-
DPSCs, a higher degree of osteogenic differentiation was observed when 
compared to I-DPSCs without neutralizing IL-6 based on weaker Alizarin Red 
staining and stronger expression of osteogenic markers including OCN and Runx2. 
Runx2 65KD
ß-Actin 42KD
Runx2 65KD
ß-Actin 42KD
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Figure 10. The expression of neurogenic markers in H-DPSC and I-DPSC in 
immunofluorescence and western blotting   
  
  10a. H-DPSC-MAP2     10b. H-DPSC with additive IL6-MAP2 
    
  10c. H-DPSC-NeuN     10d. H-DPSC with additive IL-6-NeuN 
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  10g. I-DPSC-NeuN         10h. I-DPSC with neutralizing IL6-NeuN 
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Figure 10i. Western Blotting with NeuN 
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            Figure 10j. Western Blotting with GAD6 
 
 
Immunofluorescence staining and western blotting analysis were performed to 
assess the effect of IL-6 on neurogenic differentiation potentials of DPSCs. With 
addition of IL-6, the neurogenic differentiation potentials of H-DPSCs seemed to be 
decreased based on less immunofluorescence staining and weaker expression of 
neurogenic markers including NeuN and GAD6. However, based on quantification 
analysis from immunofluorescences, H-DPSCs without additional IL-6 had 97.2% 
(±2.3%) for MAP2 and 98.3% (±1.2%) for NeuN for positively stained cells, while 
H-DPSCs with additional IL-6 had 81.7% (±7.8%) for MAP2 and 88.4% (±3.6%) for 
NeuN for positively stained cells. For I-DPSCs, there were 68.5% (±13.4%) for 
MAP2 and 61.8% (±11%) for NeuN for positively stained cells, while I-DPSCs with 
neutralizing IL-6 had 95.3 % (±3.2%) for MAP2 and 86.7 % (±5.8%) for NeuN for 
positively stained cells.  
 
GAD6 65KD
ß-Actin 42KD
GAD6 65KD
ß-Actin 42KD
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Discussion 
The differences on baseline characteristics, including expressions for stem cell 
markers, proliferation rate, and differentiation potentials, for H-DPSCs and I-
DPSCs have been thoroughly investigated by many different groups. However, the 
results from these studies vary from one another, and there is no general 
consensus yet. For example, Alongi et al. in 2010 showed that H-DPSCs have 
higher osteogenic differentiation potentials and express lower levels of MSC 
markers including STRO-1, CD90, CD105 and CD146 when compared to I-DPSCs, 
while Wang et al. in 2010 showed that H-DPSCs showed similar STRO-1 
expression and osteogenic induction potentials when compared to I-DPSCs (Alongi 
et al. 2010 & Wang et al. 2010). However, Pereira et al. in 2012 showed that there 
are more significant differences between each patient than there are between H-
DPSCs and I-DPSCs. In addition, there are not many literatures that assess the 
difference between H-DPSCs and I-DPSCs on their neurogenic differentiation 
potentials. Since there is no general consensus, experiments were performed to 
investigate the baseline characteristics of H-DPSCs and I-DPSCs for their 
proliferation rate by counting colony-forming unit and BrdU staining, stem cell 
markers, and osteogenic and neurogenic differentiation potentials. 
 
In order to investigate the general morphology of healthy and inflamed pulp tissues, 
H & E staining was performed on two healthy pulp tissues collected from impacted 
third molars and on two inflamed pulp tissues collected from severely decayed 
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molars from paraffin sections. As expected, healthy pulp tissues were devoid of 
immune cells, while inflamed pulp tissues were saturated with them. This result 
confirms our selection criteria for choosing healthy and inflamed pulp tissues.  
 
Immunofluorescence staining was performed to assess the difference between 
healthy and inflamed pulp tissues from the paraffin sections from the same 
samples that were used for H & E staining. CD105 was used as a stem cell marker 
while CD3 and IL-6 were used as indicators for inflammation. Quantification 
analysis was performed to assess how many cells are positively stained with 
secondary antibodies for fluorescence. Five fields were randomly selected at 40 
times magnification, and cells stained with DAPI and fluorescence were counted 
for the analysis. For CD 105, there were 12.4% (±1.8) and 15% (±4.2) positively 
stained cells for healthy and inflamed pulp tissues, respectively. Healthy pulp 
tissues had 4.69% (±2.8) and 4.4 %(±2.9) positively stained cells for CD3 and IL6 
respectively, while inflamed pulp tissues had 19.3% (±4.0) and 17.7% (±5.8) 
positively stained cells for CD3 and IL-6 respectively. Interestingly, results showed 
that there is no statistical difference between healthy and inflamed tissues for 
CD105 (p=0.21) while there were statistical differences for CD3 (p=0.000029) and 
IL-6 (p=0.00032), indicating that the concentration of DPSCs do not change much, 
while levels of CD3 and IL-6 are increased during inflammation. 
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In order to examine the proliferation rate of H-DPSCs and I-DPSCs, the colony 
forming unit (CFU) and BrdU staining were analyzed. During primary culturing for 
DPSCs, 10,000 cells for counted for four samples for H-DPSCs and I-DPSCs, and 
were plated for assessing colony forming unit. For the first passage DPSCs grow in 
colonies, and the number of these colonies represents the proliferation of each cell 
line (Gronthos et al., 2000). After two weeks, cells were stained with Toluidine Blue 
and colonies were defined as cells with more than 50 cells. The mean number of 
colonies for H-DPSCs was 32 ± 14.4 and for I-DPSCs, it was 13.75 ±7.9. 
According to our statistical analysis, there was no statistical difference between H-
DPSCs and I-DPSCs (p=0.068), even though H-DPSCs tended to have higher 
number of CFU’s than I-DPSCs. This could be due to small sample size.  
 
Additionally, BrdU staining was performed to further assess the proliferation rate of 
DPSCs. BrdU stands for bromodeoxyuridine which is a synthetic nucleoside, and it 
can be incorporated into the DNA of replicating cells by replacing thymidine during 
DNA replication; therefore, it’s used for detecting proliferation cells (Lehner et al. 
2011). For H-DPSCs, 70.3% (±7.6) cells were stained with BrdU, while 49.16% 
(±4.1) were stained for I-DPSCs. The statistical analysis indicated that there is a 
statistical significant difference between H-DPSCs and I-DPSCs (p=0.0006).  
 
In addition, the flow cytometric analysis was performed to assess the purity of cell 
cultures and to investigate if there is any difference between H-DPSCs and I-
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DPSCs. Markers that were evaluated include CD44, CD73, CD90, CD105, CD34 
and CD45. CD44 is a cell membrane glycoprotein with lymphocyte activation 
function, and its expression has been detected on DPSCs (Kawashima, 2012). 
CD73 is also a positive marker for DPSCs and it is a cell adhesion molecule 
(Alongi et al., 2012). CD90 is a glycoprotein expressed mainly in leukocytes and is 
another positive marker for DPSCs (Kawashima, 2012). CD105 is also known as 
endoglin which is a glycoprotein associated with the human vascular endothelium, 
and is expressed on DPSCs (Rius et al. 1998). CD34 and CD45 are both 
hematopoietic markers with CD34 commonly found in hematopoietic stem cells 
and in endothelium and CD45 being a common leukocyte antigen, and these two 
markers to be absent on DPSCs (Gronthos et al. 2000). For positive markers 
including CD44, CD73, CD90, and CD105, both H-DPSCs and I-DPSCs had high 
positive values, and they were both negative for CD34 and CD45 according to the 
flow cytometric analysis. These results indicate that cell cultures included purely of 
DPSCs, and there is no significant difference between H-DPSCs and I-DPSCs on 
the expression level for stem cell markers.  
 
IL-6 is involved in various steps through inflammatory processes, including 
induction of synthesis of neutrophils and acute phase proteins. It is also involved in 
coordination of the activity of the innate and adaptive immunities through 
stimulation of antibody production and effector T cell development (Tanaka et al., 
2014). Although many attempts have been made to investigate the function of IL-6, 
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little is known about its role in pulpal inflammation. One of the first studies on IL-6 
from the dental field was done by Barkhordar et al. in 1999 where they showed that 
there is an elevated level of IL-6 in inflamed pulp tissues and periapical lesions 
compared to the healthy pulp tissues. Many studies, including Park in 2002 and 
Sabir & Sumidartia in 2016, showed similar results where the level of IL-6 is 
increased in inflamed pulp tissues. Based on these findings, our study conducted 
an experiment to assess if I-DPSCs can play a role in increasing the level of IL-6. 
According to the statistical analysis from ELISA, I-DPSCs expressed a higher level 
of IL-6 compared to H-DPSCs (p<0.01). This result indicates that during 
inflammation, DPSCs become activated to release IL-6.  
 
Before investigating further into the role of IL-6, the baseline osteogenic and 
neurogenic differentiation potentials were assessed for H-DPSC and I-DPSC 
samples. As Pereira et al. in 2012 demonstrated that the differentiation potentials 
vary among each sample. In this study, all four samples of H-DPSCs and another 
four samples of I-DPSCs showed osteogenic and neurogenic differentiation 
potentials, but as seen in figures 7 and 8, there were significant differences. When 
compared to I-DPSCs, H-DPSCs had lower differentiation potentials for 
osteogenesis, based on Alizarin Red staining and western blotting analysis for 
osteogenesis markers including Runx2 and OCN. However, H-DPSCs had higher 
neurogenic differentiation potentials compared to I-DPSCs based on 
immunofluorescence staining for neurogenic markers including MAP2 and NeuN, 
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and western blotting analysis for GAD6 and NeuN. The quantification analysis for 
immunofluorescence staining was done, and there was statistical difference 
between H-DPSCs and I-DPSCs for MAP2 (p=0.0038) and NeuN (p=0.00011). 
This result indicates that H-DPSCs have higher neurogenic differentiation 
potentials from our samples. The effects of inflammatory processes on MSCs could 
be a controversial topic. However, in general, when the levels of pro-inflammatory 
cytokines including TNF-α, IL-1β, and INF-γ are elevated, pulp tissue regeneration 
and dentinogenic differentiation potentials of DPSCs are decreased along with 
collagen synthesis, odotogenesis and proliferation rates (Alongi et al., 2010). 
Although the samples from our study show that H-DPSCs have higher proliferation 
and neurogenic differentiation potentials with lower osteogenic differentiation 
potentials compared to I-DPSCs, it does not implicate that inflammation leads to 
such findings, because there are other factors involved and our sample size was 
small to make such generalization.  
 
Lastly, the role of IL-6 on the differentiation potentials for DPSCs were evaluated. 
Based on our result from ELISA, I-DPSCs contained higher level of IL-6 in their cell 
culture, while H-DPSCs contained minimum amount of IL-6. Therefore, IL-6 was 
added to the cell culture of H-DPSCs, while neutralizing IL-6 was added to the cell 
culture of I-DPSCs. The effect of anti-human IL-6 antibodies from the same 
company on the neutralization has been investigated and proved by several 
studies, including Zou et al. 1999 and Abrams 2001. The same experiments were 
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performed to DPSCs treated with IL-6, following osteogenic and neurogenic 
induction. Based on the Alizarin Red staining and western blotting analysis, IL-6 
has a crucial role in osteogenesis for DPSCs. When IL-6 was added to H-DPSCs 
culture, it led to stronger staining for Alizarin Red and thicker bands for osteogenic 
markers including OCN and Runx2. When the activity of IL-6 was prevented by 
adding neutralizing IL-6, osteogenic potentials of I-DPSCs were reduced based on 
weaker Alizarin Red staining and thinner bands for osteogenic markers. Our results 
are in agreement with other recent studies including Balto et al. 2001 and Xie et al. 
2018, where it showed that IL-6 can lead to higher degree of osteogenesis. The 
role of IL-6 on the neurogenic differentiation potentials seemed to be the exact 
opposite of the osteogenic differentiation potentials. When IL-6 was added to H-
DPSCs, their neurogenic differentiation potentials seemed to have been reduced 
based on the lower expression for GAD6 and NeuN from the western blotting 
analysis and less immunofluorescence staining for NeuN and MAP2. Although both 
samples were highly positively stained, according to our statistical analysis, there 
was statistical difference between H-DPSCs and H-DPSCs with additive IL-6 for 
MAP2 (p=0.0026) and NeuN (p=0.0003). This could be due to weaker effect of IL-6 
on neurogenesis. When the neutralizing IL-6 was added to I-DPSCs, the 
neurogenic potentials were reduced based on less expression on western blotting 
and immunofluorescences. The quantification analysis showed that there were 
statistical differences between I-DPSCs and I-DPSCs with neutralizing IL-6 for 
MAP2 (p=0.0037) and NeuN (p=0.0027). 
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In recent years, pulpal regeneration with the use of stem cell therapies has been 
gaining much attention in the field of dental research. In 2017, Nakashima et al. 
conducted a first human clinical study to regenerate pulp tissue by transplantation 
of healthy DPSCs from wisdom teeth into pulpectomized teeth with the diagnosis of 
irreversible pulpitis. In addition, Xuan et al. 2018 showed pulpal regeneration with 
root maturation on 100% of teeth from the study population via autologous dental 
pulp stem cell implantation on necrotic immature anterior teeth. From the findings 
from our study, IL-6 has shown the ability to decrease the neurogenic 
differentiation potential of DPSCs; therefore, neutralizing IL-6 antibodies can be 
added on collagen to promote neurogenesis of DPSCs when being implanted into 
the root canal space for pulpal regeneration which enhances the clinical success. 
 
In addition, many studies are being conducted to investigate the ways to enhance 
bone healing following endodontic surgeries, commonly known as apicoectomy. In 
2011, von Arx and AlSaeed published a review paper on the use of regenerative 
techniques in apical surgery and showed that many regenerative techniques are 
being done including guided tissue and bone regeneration with membranes, 
growth factors, bone fillers or bone substitutes. They mentioned that many studies 
indicate that the regenerative techniques are needed for better outcome with 
through-and-through lesions. From our study, it was shown that IL-6 has the 
capacity to promote osteogenesis; therefore, IL-6 can be further investigated for 
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the use as regenerative technique in endodontic microsurgery to promote faster 
bone healing in the diseased area.  
 
Conclusion 
DPSCs are being thoroughly studied for their unique characteristics, not only for 
dentistry but also for medicine nowadays. Our study is one of the very first and few 
studies where the role of IL-6, another important molecule in our body, on 
interactions with DPSCs is investigated. Our results indicated that H-DPSCs and I-
DPSCs express similar amount of stem cell markers, while H-DPSCs tend to have 
higher neurogenic differentiation potentials and proliferation rate, and lower 
osteogenic differentiation potentials when compared to I-DPSCs, although there 
are variations among each samples. Furthermore, our results showed that the level 
of IL-6 was elevated in the cell culture of I-DPSCs, which may indicate that I-
DPSCs are involved in the production of IL-6. In addition, IL-6 is capable of 
promoting osteogenesis while inhibiting neurogenesis as seen by our results.  
Our study is a pilot study where we showed that IL-6 has an effect on the 
differentiation potentials of DPSCs. Further studies are required to examine the 
detailed pathway of IL-6 interaction with DPSCs to develop the idea into promoting 
healing capacities of DPSCs for pulpal regeneration and periapical bone healing. 
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